Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 5/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1954556 | 1.00 | ADORA2B (0.53) | ADORA2BADORA3ADORA2AMAOB | |
| SCHEMBL14142760 | 0.72 | ADORA2B (0.57) | ADORA2BADORA3ADORA2A | |
| SCHEMBL561427 | 0.69 | ADORA2B (0.55) | ADORA2B | |
| SCHEMBL561426 | 0.69 | ADORA2B (0.55) | ADORA2B | |
| SCHEMBL18113976 | 0.67 | ADORA2B (0.48) | ADORA2BADORA3ADORA2A | |
| SCHEMBL7396869 | 0.67 | KDM4E (0.62) | ADORA2BADORA2A | |
| SCHEMBL7396871 | 0.67 | KDM4E (0.62) | ADORA2BADORA2A | |
| SCHEMBL3423318 | 0.66 | ADORA2B (1.00) | ADORA2BADORA3ADORA2A | |
| SCHEMBL4636767 | 0.66 | ADORA2B (0.56) | ADORA2BADORA3ADORA2AMAOB | |
| SCHEMBL8118096 | 0.66 | ADORA2A (0.63) | ADORA2BADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002416-A1 | MRGPRX4 Agonists and Antagonists | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2024-01-04 | — | — | US | disclosed |
| EP-4229059-A1 | 3-SUBSTITUTED XANTHINE DERIVATIVES AS MRGPRX4 RECEPTOR MODULATORS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022079245-A1 | 3-SUBSTITUTED XANTHINE DERIVATIVES AS MRGPRX4 RECEPTOR MODULATORS | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2022-04-21 | — | — | WO | disclosed |
| EP-2507210-B1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| EP-2507210-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | Novartis AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011067306-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002416-A1 | MRGPRX4 Agonists and Antagonists | MRGPRX4, MRGPRX1, MRGPRX2 | ADORA2B 262/4885ADORA3 150/4885ADORA2A 207/4885 |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | CYP3A5, CYP11B2, CNR2 | ADORA2B 589/4885ADORA3 680/4885ADORA2A 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.